Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1F | O60840 | 2/20 | 0.46 |
| ▸ | CACNA1D | Q01668 | 2/20 | 0.46 |
| ▸ | CACNA1S | Q13698 | 2/20 | 0.46 |
| ▸ | CACNA1C | Q13936 | 2/20 | 0.46 |
| ▸ | PTGES | O14684 | 1/20 | 0.42 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.42 |
| ▸ | MMP1 | P03956 | 1/20 | 0.41 |
| ▸ | MMP12 | P39900 | 1/20 | 0.41 |
| ▸ | PRKCA | P17252 | 1/20 | 0.41 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.41 |
| ▸ | GUSB | P08236 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | DHFR | P00374 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5765068 | 0.90 | PRKCA (0.53) | CACNA1FCACNA1DCACNA1SCACNA1CPTGES | |
| SCHEMBL5793224 | 0.87 | CACNA1F (0.43) | CACNA1FCACNA1DCACNA1SCACNA1CPTGES | |
| SCHEMBL5767223 | 0.87 | ALDH1A1 (0.43) | ALDH1A1DHFRCA1CA2MAPT | |
| SCHEMBL5767258 | 0.86 | ALDH1A1 (0.47) | ALDH1A1MMP12GAADHFRCA1 | |
| SCHEMBL5765288 | 0.85 | ALDH1A1 (0.44) | CACNA1FCACNA1DCACNA1SCACNA1CALDH1A1 | |
| SCHEMBL5767506 | 0.83 | ALDH1A1 (0.40) | CACNA1FCACNA1DCACNA1SCACNA1CALDH1A1 | |
| SCHEMBL5764738 | 0.82 | ALDH1A1 (0.44) | ALDH1A1GAADHFRCA1CA2 | |
| SCHEMBL5767327 | 0.82 | ALDH1A1 (0.43) | ALDH1A1GAADHFRCA1CA2 | |
| SCHEMBL5821119 | 0.82 | ALDH1A1 (0.43) | ALDH1A1GAADHFRCA1CA2 | |
| SCHEMBL5767067 | 0.81 | CACNA1F (0.53) | CACNA1FCACNA1DCACNA1SCACNA1CALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060116390-A1 | Hepatitis c virus inhibitors | LG LIFE SCIENCES LTD. (KR) | 2006-06-01 | — | — | US | disclosed |
| EP-1633725-A1 | HEPATITIS C VIRUS INHIBITORS | LG Life Sciences Ltd. (KR) | 2006-03-15 | — | — | EP | disclosed |
| WO-2004111013-A1 | HEPATITIS C VIRUS INHIBITORS | LG LIFE SCIENCES LTD. (KR) | 2004-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060116390-A1 | Hepatitis c virus inhibitors | HAVCR2, LIPC, FABP1 | CACNA1F 4796/4885CACNA1D 4868/4885CACNA1S 4871/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.